News Image

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Provided By GlobeNewswire

Last update: Sep 4, 2025

Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here

Read more at globenewswire.com

AIM IMMUNOTECH INC

NYSEARCA:AIM (9/23/2025, 8:04:00 PM)

After market: 2.7185 +0.07 (+2.78%)

2.645

-0.2 (-7.03%)



Find more stocks in the Stock Screener

Follow ChartMill for more